ghk-cu copper peptide hair growth evidence review GHK Clinical Trial (2016) — Research Summary Thermodynamically stable ionic liquid microemulsions

Journal of Holistic Integrative Pharmacy

Retatrutide is at the Phase 3 stage, and the cagrilintide-plus-semaglutide combination CagriSema was reported to have a New Drug Application under FDA review, but a filing under review is not an approval

Mechanism: Acts as a signal peptide that modulates fibroblast activity, collagen and glycosaminoglycan synthesis, antioxidant signaling, and copper bioavailability [1][2]

This synergistic formulation targets several hallmarks of aging (chronic inflammation, oxidative stress, vascular decline, and collagen loss) to promote youthful structural integrity and enhanced cellular function 1 -5

Clinical experience strongly supports its use for the indications below but we're working with promising preclinical data, not robust human RCTs

Compounded injectable GHK-Cu is dispensed pursuant to a patient-specific prescription and is not an FDA-approved drug